Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-6 Sublingual Tablet for Acute Perforating Artery Infarction
CTR20262641Phase 3Active
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cilostazol in brain infarction, sponsored by Nanjing NeuroDawn Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
cilostazol
03
Conditions
brain infarction
Beyond the preview
Go deeper on CTR20262641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262641.